The dual benefit of tirzepatide in patients with type 2 diabetes: glycemic control and simultaneous weight loss. Tirzepatide: the first dual GLP-1/GIP agonist. Mounjaro (tirzepatide) is the first medication to simultaneously activate GLP-1 and GIP receptors, two essential incretin hormones in glucose regulation and energy metabolism. … Read more
Hypoglycemia with tirzepatide is rare due to its glucose-dependent action. However, certain situations increase the risk. One of the major advantages of tirzepatide compared to older antidiabetic treatments is its low risk of hypoglycemia. This safety is linked to its glucose-dependent mechanism of action. However, certain clinical situations warrant particular vigilance. Why is the risk … Read more
The SURMOUNT-2 study demonstrates that tirzepatide is equally effective in patients combining type 2 diabetes and obesity, with major glycemic benefits. Following the spectacular results of SURMOUNT-1 in non-diabetic patients, the question arose: would tirzepatide be as effective in patients simultaneously presenting with type 2 diabetes … Read more